Business Wire

Mary Kay Inc. Sponsors University of the Philippines Medical Alumni Society of America 34th Annual Grand Convention

Share

Mary Kay Inc ., a leading skincare innovator, continued its decades-long commitment to science through its sponsorship of the University of the Philippines Medical Alumni Society of America (UPMASA) 34th Annual Grand Convention (AGC) in Dallas. The conference, held at the Fairmont Hotel from July 2 – July 6, convened more than 500 doctors from the U.S. and the Philippines to discuss topics ranging from dermatology to orthopedics and neurology.

UPMASA is a non-profit organization that provides healthcare assistance and supports medical education in the Philippines. With 20 chapters and a membership base of over 2,000 medical doctors who are mostly in the USA and in the Philippines, members include those in clinical practice, research, academic medical education and community endeavors.

“We’re honored to attend and sponsor events like the UPMASA annual convention in order to advance technology and education around health and skincare,” said Dr, Lucy Gildea, Chief Scientific Officer at Mary Kay. “We’re excited that our sponsorship will also help support the UPMASA Texas Chapter’s humanitarian efforts, benefitting the Johnson County Children's Advocacy Center and the Boys and Girls Club of Dallas.”

UPMASA supports the philanthropic activities of the University of the Philippines College of Medicine (UPCM) and the Philippine General Hospital (PGH). The organization helps the Cesium Project of the PGH Cancer Institute by providing medical supplies for treating indigent cancer patients.

At the Grand Convention, Mary Kay also hosted an exhibit featuring its TimeWise® Miracle Set 3D® and a look at the science behind its beauty products.

“Mary Kay’s generous sponsorship allows UPMASA to continue its support of healthcare and medical education in both the Philippines and North America,” said Dr. Ponciano Cruz, UPMASA AGC Chair. “It also helps us to continue to execute philanthropic activities such as faculty endowments, medical student scholarships, and physical infrastructure and equipment through the Philippines General Hospital.”

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, manufacture irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay Foundation℠, the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ResMed Inc. Completes $500M Private Placement Debt Offering15.7.2019 20:05:00 CESTPress release

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility. The notes are senior unsecured obligations of ResMed, and jointly and severally guaranteed by each Subsidiary Guarantor. “We are pleased to complete this U.S. private placement offering on attractive terms,” said Brett Sandercock, ResMed’s chief financial officer. “The transaction significantly lengthens our average debt maturity profile and provides improved visibility on our long-term funding costs.” This private placement offering is exempt from the registration requirements of t

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test15.7.2019 15:00:00 CESTPress release

SpeeDx Pty. Ltd. today announced Resistance Plus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mgen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005544/en/ (Photo: Business Wire) Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing.1 Now Canadian laboratories can utilize Resistance Plus MG and bring this service inhouse to generate more timely results for doctors and their p

Mouser Electronics Now Stocking Broad Portfolio of Xilinx Products15.7.2019 14:55:00 CESTPress release

Mouser Electronics, Inc. today announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing, to stock one of the industry’s broadest portfolios of Xilinx products, including digital downloads of development software and IP. Xilinx is the inventor of the FPGA, hardware programmable system-on-chips (SoCs) and the adaptive compute acceleration platform (ACAP), designed to deliver the most dynamic processor technology in the industry and enable the adaptable, intelligent and connected world of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005546/en/ Mouser Electronics proudly announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing. Mouser will stock one of the industry’s broadest portfolios of Xilinx products. (Graphic: Business Wire) To learn more, visit www.mouser.com/xilinx. “Xilinx is an industry

Rimini Street Becomes Support Service Provider for Hyundai-Kia Motors’ Global Database Portfolio15.7.2019 13:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005161/en/ Rimini Street announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. (Photo: Business Wire) By providing efficient, timely, and cost-effective database maintenance and support, Rimini Street plans to actively support Hyundai-Kia Motors in their endeavor to implement a business-driven IT roadmap. Cost Optimization and Desire for Quality Support To support response to paradigm shifts in the automobile industry and active technology innovation, Hyundai-Kia Motors se

Värde Partners Appoints Co-CEO15.7.2019 12:12:00 CESTPress release

Värde Partners, a leading global alternative investment firm, today announced that Ilfryn Carstairs will join George Hicks, Co-Founder and Chief Executive Officer, as Co-CEO, effective January 1, 2020. George co-founded Värde Partners 25 years ago and intends to transition to an Executive Chair role in 2022. Ilfryn will retain his role as Global CIO. “Transition is a process and involves the entirety of the firm. The roles Ilfryn and I play are just part of that process whereby a new generation of leaders succeed the founders,” said George. “Ilfryn joined us 12 years into this journey and has grown as both an investor and a leader. His skills in both pursuits will enable Värde to continue delivering for our investors and will help to ensure that we maintain our strong culture long into the future.” Ilfryn is a Partner and Co-Chief Investment Officer overseeing the global investment strategy for Värde. He co-chairs the firm’s Investment Committee. Based in Singapore since 2017, he joine

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform15.7.2019 12:00:00 CESTPress release

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform. “Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “We want to pioneer new paradigms